The use of doravirme as part of antiretroviral therapy regimens in patients with resistance mutations
- Autores: Orlova-Morozova E.A.1, Pronin A.Y.1
-
Afiliações:
- Moscow Regional Center for Prevention and Control of AIDS and Communicable Diseases
- Edição: Volume 11, Nº 3 (2021)
- Páginas: 96-99
- Seção: Articles
- URL: https://journals.eco-vector.com/2226-6976/article/view/287796
- DOI: https://doi.org/10.18565/epidem.2021.11.3.96-9
- ID: 287796
Citar
Texto integral
Acesso aberto
Acesso está concedido
Acesso é pago ou somente para assinantes
Resumo
The paper deals with a clinical experience in following up 12 HIV-infected patients with a history of multiple switches to ART regimens and with resistance mutations, who have been switched to an ART DOR/3TC/TDF + DTG regimen in routine clinical practice. The available HIV-1 RNA data show that at one month after switching to a new regimen, 8 of the 12 patients and at 6 month, 8 of the 9 patients achieved an undetectable viral load. Further patient follow-up is needed.
Palavras-chave
Texto integral
Sobre autores
Elena Orlova-Morozova
Moscow Regional Center for Prevention and Control of AIDS and Communicable Diseases
Email: orlovamorozova@gmail.com
Cand. Med. Sci., Head, Outpatient Department
Alexander Pronin
Moscow Regional Center for Prevention and Control of AIDS and Communicable Diseases
Email: alexanderp909@gmail.com
Cand. Med. Sci., Head
Bibliografia
- Всемирная организация здравоохранения. Глобальная стратегия сектора здравоохранения по ликвидации ВИЧ на 2016-2021. 2016. https://apps.who.int/iris/bitstream/handle/10665/255763/WHO-HIV-2016.05-rus.pdf;jsessionid=09 DCDD724175F1C737E6A1797499F575?sequence=1
- Государственная стратегия противодействия распространению ВИЧ- инфекции в Российской Федерации на период до 2020 года и дальнейшую перспективу. Утверждена Распоряжением Правительства РФ от 20.10.2016 № 2203-р. http://government.ru/docs/24983/
- Уровень и структура лекарственной устойчивости ВИЧ среди наивных пациентов в Российской Федерации. Анализ Российской базы данных лекарственной устойчивости ВИЧ. www.hivresist.ru
- База данных лекарственной устойчивости ВИЧ Стэнфордского университета. https://hivdb.stanford.edu/dr-summary/resistance-notes/NRTI/#16Larder1995
- Cot6 B., Burch J.D., Asante-Appiah E., Bayly Ch., B6dard L, Blouin M. еt al. Discovery of MK-1439, an orally bioavailable non-nucleoside reverse ranscriptase inhibitor potent against a wide range of resistant mutant HIV viruses. Bioorg. Med. Chem. Lett. 2014; 24(3): 917-922. doi: 10.1016/j.bmcl.2013.12.070
- Feng M., Sachs N.A., Xu M., Grobler J., Blair W., Hazuda D.J. et al. Doravirine suppresses common nonnucleoside reverse transcriptase inhibitor-associated mutants at clinically relevant concentrations. Antimicrob Agents Chemother. 2016; 60(4): 22412247. doi: 10.1128/AAC.02650-15
- Orkin C., Molina J.-M., Lombaard J., DeJesus E., Rodgers A., Kumar S. et al. Once-daily Doravirine in Human Immunodeficiency Virus Type 1-Infected, Antiretroviral-naive Adults: An Integrated Efficacy Analysis. Clin. Infect. Dis. 2020; 70(7): 1344-1352. doi: 10.1093/cid/ciz424
- Johnson M., Kumar P., Molina J.-M., Rizzardini G., Cahn P., Bickel M. et al. for the DRIVE-SHIFT Study Group. Switching to Doravirine/Lamivudine/ Tenofovir Disoproxil Fumarate (DOR/3TC/TDF) Maintains HIV-1 Virologic Suppression Through 48 Weeks: Results of the DRIVE-SHIFT Trial. J. Acquir. Immune Defic. Syndr. 2019; 81(4): 463 -472. doi: 10.1097/ QAI.0000000000002056
- Wong A., Goldstein D., Mallolas J., DeJesus E., Johnson M., J.-M. Molina J.-M. et al. Efficacy and Safety of Doravirine/ Lamivudine/Tenofovir Disoproxil Fumarate (DOR/3TC/ TDF) in Treatment-Naive Adults With HIV-1 and Transmitted Nonnucleoside Reverse Transcriptase Inhibitor Resistance Mutations. J. Acquir. Immune Defic. Syndr. 2019; 82(4): e47-e49. doi: 10.1097/QAI.0000000000002153
- Soulie C., Santoro M.M., Charpentier C., Storto A., Paraskevis D., Di Carlo D. et al. Rare occurrence of doravirine resistance-associated mutations in HIV-1-infected treatment-naive patients. J. Antimicrob. Chemother. 2019; 74(3): 614-617. doi: 10.1093/jac/ dky464
Arquivos suplementares
